Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer

21. september 2011 oppdatert av: Shanghai CP Guojian Pharmaceutical Co., Ltd.

An Open-Label Randomized Phase II Study of Cipterbin® or Cipterbin® in Combination With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer (MBC)

The HER2 gene (also known as HER2/neu and ErbB2 gene) is overexpressed in 20-30% of human breast cancers and leads to a particularly aggressive form of the disease. Trastuzumab,a humanized anti-HER2/neu receptor monoclonal antibody, has been proved a valuable treatment for HER2-positive breast cancer patients.The combination of trastuzumab with chemotherapy has been shown to increase both survival and response rate, in comparison to trastuzumab alone. CMAB302, a biosimilar of trastuzumab, was developed by Shanghai CP Guojian Pharmaceutical Co.Ltd. Efficacy and safety of CMAB302 as a single agent or in combination with vinorelbine were evaluated in patients with HER2-overexpressing metastatic breast cancer.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

The HER2 gene (also known as HER2/neu and ErbB2 gene) is overexpressed in 20-30% of human breast cancers and leads to a particularly aggressive form of the disease. Trastuzumab,a humanized anti-HER2/neu receptor monoclonal antibody, has been proved valuable treatment for HER2-positive breast cancer patients.The combination of trastuzumab with chemotherapy has been shown to increase both survival and response rate, in comparison to trastuzumab alone. CMAB302, a biosimilar of trastuzumab, was developed by Shanghai CP Guojian Pharmaceutical Co.Ltd. Previous Phase I study showed that CMAB302 was well tolerated as monotherapy and the pharmacokinetic data exhibited a non-linear profile over the dose range of 100 to 500 mg, similar to that of trastuzumab. In this study, efficacy and safety of CMAB302 as a single agent or in combination with vinorelbine were evaluated in patients with HER2-overexpressing metastatic breast cancer.

Studietype

Intervensjonell

Registrering (Faktiske)

109

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Kina
      • Beijing, Kina, 100021
        • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 70 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • pathologic diagnosis breast cancer
  • HER2+ status defined as IHC3+ Staining or in situ hybridization positive at least 1 measurable lesion as per RECIST criteria
  • Adequate bone marrow function (absolute neutrophil count >1500/mm3, platelet count >100.000/mm3, hemoglobin >10gr/mm3)
  • Adequate liver (bilirubin <1.0 times upper limit of normal and SGOT/SGPT <2.5 times upper limit of normal) and renal function (creatinine <1.5mg/dl)
  • Adequate cardiac function (LVEF>50%). Normal electrocardiogram and absence of significant heart disease
  • age from 18 to 70y
  • Karnofsky performance score ≥ 60
  • Life expectancy of greater than 3 months
  • Negative HCG pregnancy test for premenopausal women of reproductive capacity and for women less than 12 months after the menopause.
  • signed ICF

Exclusion Criteria:

  • prior exposure vinorelbine for breast cancer
  • prior exposure trastuzumab for breast cancer
  • Prior chemotherapy and radiation therapy within the last 4 weeks before enrollment
  • use of any other investigational agents within the last 4 weeks before enrollment
  • symptomatic, central nervous system metastases
  • Hypersensitivity to trial medications
  • breastfeeding or pregnant

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: combination agent group
Legemiddel: humanized anti-HER2 antibody
Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an intravenous infusion over 30 minutes weekly for 12 weeks. For single agent group, patients with complete response, partial response or stable disease could be treated for 24 weeks.
Andre navn:
  • brand name:Cipterbin®
Legemiddel: Vinorelbine
Vinorelbine was administered weekly at a dose of 25 mg/m2 on day 1, 8 and 21 every 4 weeks
Andre navn:
  • brand name:NAVELBINE®
Eksperimentell: single agent group
In this arm, patients would be treated with Cipterbin® for 12 or 24 weeks
Legemiddel: humanized anti-HER2 antibody
Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an intravenous infusion over 30 minutes weekly for 12 weeks. For single agent group, patients with complete response, partial response or stable disease could be treated for 24 weeks.
Andre navn:
  • brand name:Cipterbin®

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall response rate
Tidsramme: up to 24 weeks
according to RECIST 1.0 (Response Evaluation Criteria In Solid Tumors)
up to 24 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
One-year survival rate
Tidsramme: 1 year
1 year
Number of participants with adverse events
Tidsramme: up to 24 weeks
Adverse events was recorded according to NCI CTC 2.0 (National Cancer Institute common toxicity criteria).
up to 24 weeks
Overall control of disease
Tidsramme: up to 24 weeks
defined as overall response rate plus stable disease, by RECIST 1.0
up to 24 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Shanghai CP Guojian Pharmaceutical Co., Ltd.

Etterforskere

  • Studiestol: Yan Sun, PhD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
  • Studieleder: Yuankai Shi, PhD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
  • Hovedetterforsker: Zefei Jiang, PhD, Hospital Affiliated to Academy Military Medical Science
  • Hovedetterforsker: Jun Ren, PhD, Peking University Cancer Hospital & Institute
  • Hovedetterforsker: Kai Li, PhD, Tianjin Medical University Cancer Institute and Hospital
  • Hovedetterforsker: Dong Wang, PhD, Daping Hospital & Research Institute of Surgery of the Third Military Medical University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. juli 2005

Primær fullføring (Faktiske)

1. februar 2007

Studiet fullført (Faktiske)

1. mai 2007

Datoer for studieregistrering

Først innsendt

21. september 2011

Først innsendt som oppfylte QC-kriteriene

21. september 2011

Først lagt ut (Anslag)

23. september 2011

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

23. september 2011

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. september 2011

Sist bekreftet

1. juni 2005

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • C302MBCⅡ

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere